ARCHIVES

Over Half of ALK-Positive NSCLC Patients Responded To Crizotinib In Colorado Study

This article is from The Cancer Letter archive.

Vol. 33 No. 11 | November 26, 2010

Download PDF Visit The Full Archive

Related Articles

DCT Board Approves Phase 2/3 Studies Of LAK-IL-2

February 14, 1986

AACR Membership Up 14 Percent Per Year Since ‘88

June 8, 1990

Practice Management Giant US Oncology To Sell Practices Back to Physicians.

October 5, 2001

(8-page issue).

January 31, 2003

NIH Funding Strategies, UICC Fellowships

December 4, 1992

Wyngaarden Recommendation On New Director Due Nov. 1o; Five Staff Members Nominated

November 4, 1988